STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.LONDON — Half a year into taking over the job, GSK CEO Luke Miels on Tuesday laid out his plans to turn the U.K. pharma giant into a more agile company with years of growth ahead. A key step, Miels said, will be a three-year campaign to generate 1.9 billion pounds (about $2.5 billion) in annual savings by 2029, much of which will be reinvested to advance the company’s late-stage pipeline. The company also now plans to start at least 20 Phase 3 trials this year, up from the 10 that it had disclosed at the beginning of 2026. “We are step-by-step building a set of potential best-in-class products across our core therapy areas,” Miels said, a list that includes some newer target areas — like oncology and liver disease — as well as longtime GSK focuses like vaccines and HIV. Miels would not say Tuesday how many jobs would be cut under the savings drive. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe